Enyiopharma is a biopharmaceutical company that specializes in the development and commercialization of innovative therapies to address unmet medical needs. The company focuses on the discovery and development of new drugs, with a particular emphasis on oncology and autoimmune diseases.

Enyiopharma

ENYO Pharma is developing innovative therapeutics based on fibrolytic and anti-inflammatory properties for diseases with impaired kidney function.

The company is conducting Phase 2 trials with its lead compound Vonafexor in Chronic Kidney Diseases (CKD) and rare kidney disease such as Alport syndrome, and liver diseases (such as Non-Alcoholic SteatoHepatitis, NASH).

Liver-related infectious diseases such as chronic Hepatitis B and Hepatitis D are also addressed with Vonafexor.

EASME - EU Executive Agency for SMEs

Sofinnova Partners

Morningside Venture Investments

Sofinnova Investments

Bpifrance

InnoBio

Inserm Transfert Initiative

OrbiMed

Andera Partners

ENYO Pharma

ENYO Pharma is supporting and attending "The 2024 International Workshop on Alport Syndrome" organized by Alport Syndrome Alliance and hosted by biobank.cy Center of Excellence in Biobanking and Biomedical Research in Cyprus.

It is a very great opportunity to meet Alport patients, researchers, clinicians, drug developers from all over the world to better understand Alport Syndrome disease. ENYO Pharma is also presenting its starting Phase 2 ALPESTRIA-1 study with Vonafexor.

This workshop was also the best place yesterday to celebrate the World Kidney Day!

#alportsyndrome #clinicaltrials #orphandrugs #inflammation #fibrosis #kidneydisease


ENYO Pharma is excited be part of the 6th CKD Drug Development Summit (Boston, MA), March 20th-21st! 

Jacky Vonderscher, our CEO, will be speaking on “Developing antifibrotic and anti-inflammatory therapeutics in clinical stage for common and rare renal diseases including CKD and Alport syndrome” on Day 2 at 11.30-12.00.

Together with Pete Leone, our Head of BD and Strategy, he will be eager to discuss about Vonafexor’s program around two posters:
- The starting Phase 2 ALPESTRIA-1 clinical study on Vonafexor for Alport syndrome
- Previous preclinical and clinical work done on Vonafexor.

ENYO Pharma is also delighted to promote and sponsor again the “6th edition of the CKD Drug Development Summit, The Definitive Industry Forum for CKD Drug Development to Advance More Personalized Therapies for Rare & Common Kidney Diseases”.

If you are interested in learning more on Vonafexor's program, please contact Jacky Vonderscher and Pete Leone

#kidneydisease #drugdevelopment #clinicaltrials 
Ellie Rapps Ellie Bilko

As today is the Rare Disease Day, ENYO Pharma takes the opportunity to announce its support as a sponsor and its participation in “The 2024 International Workshop on Alport Syndrome” organized by the Alport Syndrome Alliance and hosted by biobank.cy Center of Excellence in Biobanking and Biomedical Research on March 14-16 in Cyprus.

💊 Our clinical team is ready to present our starting Phase II ALPESTRIA-1 clinical study with Vonafexor on Alport Syndrome. The 7th edition of the workshop will spotlight the latest developments in this rare kidney disease and give the opportunity for Alport community to connect, update and discuss the latest research.

👨‍⚕️ Alport syndrome is a rare kidney disease, a genetic disorder affecting 1 in 5,000-10,000 live births. It is characterized by a progressive loss of kidney function and may result in hearing loss and eye abnormalities. To date, no specific treatment is available for patients suffering from Alport syndrome.
 
#alportsyndrome #rarediseaseday #clinicaltrial


PRESS RELEASE:

ENYO Pharma announces a €39 million Series C financing and FDA clearance (IND) to advance Vonafexor in a Phase 2 clinical trial for patients with Alport syndrome.

- The Company is initiating asap a Phase 2 clinical study of Vonafexor in Alport Syndrome - called “ALPESTRIA-1” - in the first half of 2024. 
- Series C proceeds will fund the Phase 2 study, as well as operations and further R&D through the first half of 2026.

To read the press release, please visit our website:
https://lnkd.in/e_Gt3e7W

OrbiMed Morningside Technology Advisory LLC Andera Partners Bpifrance Large Venture InnoBio Bpifrance Life Sciences Venture Sofinnova Partners INSERM TRANSFERT INITIATIVE

COM:ENYOPHARMA

Enyiopharma